Back to top

Analyst Blog

Drugstore chain retailer, Rite Aid Corporation (RAD - Analyst Report) reported marginal growth in comparable-store sales (comps) for Aug 2013. The company’s comps for the 5-week period ended Aug 31, 2013 inched up 1.1% from the prior-year period, primarily driven by better comps results at its pharmacy stores. This was however, partially offset by weak front-end comps performance.

Pharmacy comps for August were up 2.5%, which included a negative impact of nearly 161 basis points from generic drug introduction. A 0.2% drop in prescription counts also adversely affected the results. Further, the company’s front-end comps declined 1.7%.

Rite Aid reported total drugstore sales of $2.425 billion for the month, up 1.1% from the year-ago figure of $2.399 billion. Prescription sales constituted 68.4% of total drugstore sales. Third-party prescription sales accounted for 97.1% of pharmacy sales.

Rite Aid’s comps for second-quarter fiscal 2014 inched up 1.0% from the comparable year-ago quarter with pharmacy comps increasing 1.7% and front-end comps declining 0.3%. Prescription count at comparable stores remained flat year over year.

Total drugstore sales nudged up 0.7% to $6.250 billion in the quarter compared with $6.205 billion in the second quarter of fiscal 2013. Prescription sales accounted for 67.9% of total drugstore sales. Additionally, third-party prescription sales constituted 97.0% of pharmacy sales.

For the 26-week period ended Aug 31, Rite Aid’s comps dipped 0.8% from the prior-year period. The fall was primarily due to a 1.1% drop in pharmacy comps, while front-end comps remained flat year over year. Prescription count at comparable stores fell 0.1%.

In the period, total drugstore sales fell 1.0% to $12.514 billion from $12.646 billion in the comparable period of fiscal 2013. Prescription sales comprised 67.7% of total drugstore sales. Additionally, third-party prescription sales constituted 97.0% of pharmacy sales.

Rite Aid, which trails Walgreen Co. (WAG - Analyst Report) and CVS Caremark Corp. (CVS - Analyst Report) in terms of store count, has persistently witnessed a downward sales trend over several quarters due to the introduction of lower cost generic (non-brand) drugs. Such non-branded drugs are less expensive in the market but generate higher gross margins for the company.

This is evident from Rite Aid’s performance in first-quarter fiscal 2014, when generic medication primarily drove its margin expansion. Going forward, this Zacks Rank #3 (Hold) stock is likely to focus on expanding its portfolio of generic medication, given the growing demand for such drugs.

However, Rite Aid’s generic drug sales could be dented by Wal-Mart Stores Inc.’s (WMT - Analyst Report) entry into the retail generic drug market. Due to Wal-Mart’s wide array of manufacturers in India, Israel and the U.S., the mass merchant can offer the particular drugs at a more discounted price when compared to other drugstore chain retailers.

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
SUPER MICRO… SMCI 26.35 +7.59%
STRATTEC SE… STRT 85.29 +6.29%
CENTURY ALU… CENX 26.34 +5.44%
BAIDU ADS BIDU 223.01 +3.96%
TESLA MOTOR… TSLA 279.78 +3.74%